Hot Keywords
Tumor Microenvironment Exosomes and Extracellular Vesicles Breast Cancer Metastasis Bone Metastasis Metastatic Renal Cell Carcinoma Lymph node metastasis Mesothelioma Hematological Malignancies Thyroid Cancer Liquid Biopsies Early Diagnosis Lung Cancer Brain Tumors Lymphoma Oncolytic Virus Cervical Cancer Cancer Stem Cells

Top

The First Editorial Board Meeting of Journal of Cancer Metastasis and Treatment (JCMT) in 2022 was Successfully Held Online

Published on: 23 Feb 2022 Viewed: 729

The First Editorial Board meeting of the Journal of Cancer Metastasis and Treatment (JCMT) was successfully held on February 21, 2022. Ten Editorial Board members participated in the meeting.

The Editor-in-Chief, Professor Lucio Miele, presided over this meeting. Work summary of 2021 and the development plan in 2022 of JCMT were reported in this meeting.

The whole meeting included six parts:

1. Editor-in-Chief's Welcome Speech;
2. Introduction of each attendee, including names, affiliation, and research interests;
3. Introduction of OAE Publishing Inc.;
4. Work Summary in 2021 and Development Plan in 2022;
5. Free Discussion;
6. Summary and Acknowledgement.

At the beginning of the meeting, Professor Lucio Miele made a welcome speech. He was very grateful for these Editorial Board members' participation and every Editorial Board members’ contribution to JCMT in 2021. With the encouragement of the Editor-in-Chief, each attendee makes a simple self-presentation so as to know about each other and promote cohesion among our Editorial Board members. Subsequently, publisher Li-Jun Jin made a detailed introduction of OAE Publishing Inc. and the current progress of OAE journals to all attendees. She stressed that OAE will adhere to its business philosophy: scientificity, preciseness, earnestness, perfection, and devoted to high-quality academic publishing to promote scientific innovation and development.

Professor Miele presented the annual report of JCMT in 2021 to the participants, including the submissions and publications, special issues, readership, citations, and new Editorial Board members. All of these contents were shown with specific data, figures, and tables. The development and progress of JCMT in 2021 and the development plan in 2022 were clearly displayed, which are completely based on the support of the Editorial Board members.

During the free discussion section, Professor Sheue-Yann Cheng, an American molecular geneticist who pioneered the development of mouse models, gave us positive feedback: " JCMT is a journal dedicated to high-quality academic publishing for a long time, most of which are scholars from internationally renowned institutions, which has laid a certain foundation for excellent manuscript source reserves." And our Editorial Board member Professor Jan B. Vermorken, who leads the special issue "Research Progress in Head and Neck Cancers", from the Department of Medical Oncology of Antwerp University Hospital, set forth his opinion about needs and directions for a journal to encourage us to do the best.

Other Editorial Board members also put forward many constructive suggestions and ideas for JCMT. The Editorial Office will also summarize and discuss the issues after the meeting and adopt them as needed.

After a heated discussion, Professor Lucio Miele detailed JCMT's current development status, vision, and plan. JCMT will continue to adhere to high-quality publishing, fast-publication speed, rigorous peer review process, and bring more wonderful articles and webinars to the cancer treatment field in 2022.

This is the first Editorial Board meeting of JCMT in 2022. We surely believe that JCMT will bloom in the future with the guidance and support of the Editorial Board members.

Thanks for the support of the following Editorial Board members to this meeting (listed in no particular order):

Lucio Miele, the Director for Inter-Institutional Programs, LSU Health Sciences Center - New Orleans, USA.
Sheue-Yann Cheng, Gene Regulation Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jan Baptist Vermorken, the founding chair of the Gynecologic Cancer InterGroup, Universiteit Antwerpen, Belgium.
Bernard A. M. Van der Zeijst, Department of Medical Microbiology, Leiden University Medical Center, Leiden, The Netherlands.
Chao Cheng, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, USA.
Andrea Nicolini, Department of Internal Medicine, University of Pisa, Santa Chiara Hospital, Pisa, Italy.
Guofeng Xie, Department of Medicine, Division of Gastroenterology & Hepatology and Program in Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
Boris Reva, Department of Genetics and Genomic Sciences, Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pran K. Datta, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL, USA.
Maryam K Foroozesh, the Department of Chemistry, Xavier University of Louisiana, New Orleans, LA, USA.

Respectfully submitted by the Editorial Office of Journal of Cancer Metastasis and Treatment.


© 2016-2022 OAE Publishing Inc., except certain content provided by third parties